European Medical Solutions (STU:AS00) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
European Medical Solutions had a gross margin of 31.73% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
European Medical Solutions Gross Margin % Related Terms
European Medical Solutions Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:AS00 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, European Medical Solutions's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
European Medical Solutions Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, European Medical Solutions's Gross Margin % distribution charts can be found below:
* The bar in red indicates where European Medical Solutions's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
European Medical Solutions (STU:AS00) has a Gross Margin % of 31.73% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on European Medical Solutions and its competitors. This is near median its historical median of 33.23. Over the past decade, European Medical Solutions' Gross Margin % has ranged from 32.94 to 34.75. According to the industry distribution chart, European Medical Solutions ranks #548 out of 736 companies in the Biotechnology industry, placing it in the top 74.5%.
Is European Medical Solutions' Gross Margin % too high?
European Medical Solutions' current Gross Margin % of 31.73% is near median its 10-year median of 33.23. Over the past 10 years, this metric has ranged from a low of 32.94 to a high of 34.75. The Biotechnology industry median Gross Margin % is 60.91. European Medical Solutions' value of 31.73% is 47.9% below this industry median. Based on the distribution chart, European Medical Solutions ranks #548 out of 736 companies in the Biotechnology industry, which is below the industry midpoint. Overall, European Medical Solutions has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does European Medical Solutions' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, European Medical Solutions ranks #548 out of 736 companies for Gross Margin %. This places European Medical Solutions in the lower half of its industry. The industry median Gross Margin % is 60.91. European Medical Solutions' value of 31.73% is 47.9% below this benchmark. Historically, European Medical Solutions' own Gross Margin % has ranged from 32.94 to 34.75 over the past decade. While the company's 10-year median is 33.23 vs. the industry median of 60.91, European Medical Solutions has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. European Medical Solutions's current Gross Margin % of 31.73% is 47.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on European Medical Solutions and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. European Medical Solutions's current Gross Margin % is 31.73%, which is near median its own 10-year median of 33.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is European Medical Solutions stock overvalued right now?
European Medical Solutions (STU:AS00) has a current Gross Margin % of 31.73%. The stock's GF Value™ is €8.11, compared to a current price of €4.72 — trading 41.8% below its estimated fair value. The current Gross Margin % is 31.73%, which is near median its 10-year median of 33.23 and 47.9% below the Biotechnology industry median of 60.91. European Medical Solutions' overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For European Medical Solutions (STU:AS00), the current Gross Margin % is 31.73% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is European Medical Solutions (STU:AS00) Overvalued in 2026?
Based on GuruFocus' analysis, European Medical Solutions stock appears to be undervalued.
The current stock price of €4.72 is trading 41.8% below its estimated GF Value™ of €8.11.
Key valuation signals for STU:AS00:
Gross Margin %: 31.73% (near median its 10-year median of 33.23)
GF Value™: €8.11 vs. price of €4.72 (41.8% below fair value)
Industry Position: 47.9% below the Biotechnology median (#548 of 736)
No single metric tells the full story. See the STU:AS00 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
European Medical Solutions Formerly DMS Imaging SA is a clinical-stage biopharmaceutical company. The company is engaged in the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+ technology platform. Its lead product is gp-ASIT+, a phase III trial for the treatment of grass pollen rhinitis. Its pipeline products consist of hdm-ASIT+ for the treatment of house dust mite asthma; and pnt-ASIT+ for the treatment of peanut allergy.
47GF Score
Get the complete analysis for STU:AS00
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:AS00 has been successfully added to your 
